We have several clinical studies ongoing and planned with our multiTAA-specific T cell product candidates.

Based on positive results of multiTAA product candidates in various blood and solid tumor cancers, we are currently enrolling patients in two multicenter clinical studies. Our ARTEMIS study is currently enrolling patients suffering from post-transplant Acute Myeloid Leukemia, and our APOLLO study is currently enrolling patients with non-Hodgkins Lymphoma.

See clinical trials below: